Numerous outbreaks caused by the epidemic strain of C. difficile (027/NAP1/BI strain) highlight the need for rapid and accurate differentiation of C. difficile 027/NAP1/BI strains in order to stay ahead of an outbreak
Higher risk of cross contamination with 027/NAP1/BI strain due to more efficient sporulation
027/NAP1/BI strain has been identified as a cause of outbreaks around the world
Incremental costs due to C. difficile infection can be as high as $7
1799 per patient
Xpert C. difficile/Epi is the first commercially available test in the world to detect and differentiate the epidemic strain of C. difficile (027/NAP1/BI). With rapid and accurate identification of the epidemic strain
Infection control professional can stay ahead of potential outbreak
Innovative multiplex design enables detection of C. difficile Infection (CDI) and 027/NAP1/BI strain call-out in a single cartridge
On-demand testing of samples from suspected CDI patients provides on-demand epidemiological surveillance data clinicians can act on
Monitoring and reporting of the epidemic strain enables clinicians to improve infection control efforts
Cepheid’s Xpert C. difficile/Epi test provides on demand results you can trust and empowers your clinical team to better manage patients
